Company intelligence / Profile preview
AvantGuard
- Ownership
- Private
- Development stage
- Other
Overview
AvantGuard is advancing a proprietary antimicrobial compound, Avantamine, offering broad-spectrum, long-lasting, and resistance-avoidant effects. It has received multiple NIH grants for preclinical work in infection prevention (surface and medical device disinfection), dermatology (antifungals), and chronic wound management. No clinical results have yet been reported; all activity is currently preclinical and regulatory-facing.[1][5]
- Therapeutic areas
- EndocrinologyDermatologyInfectious Diseases
- Modalities
- PolymerAntimicrobial compound
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on AvantGuard.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AvantGuard.